WITHDRAWN: Utility and Work Productivity Data for Economic Evaluation of Breast Cancer Therapies in the Netherlands and Sweden

Author(s):  
Gerardus W.J. Frederix ◽  
Nuz Quadri ◽  
Anke M. Hovels ◽  
Fleur T. van de Wetering ◽  
Hans Tamminga ◽  
...  
2013 ◽  
Vol 35 (4) ◽  
pp. e1-e7 ◽  
Author(s):  
Gerardus W.J. Frederix ◽  
Nuz Quadri ◽  
Anke M. Hövels ◽  
Fleur T. van de Wetering ◽  
Hans Tamminga ◽  
...  

2010 ◽  
Vol 8 (3) ◽  
pp. 218
Author(s):  
M.F. von Meyenfeldt ◽  
M. deKok ◽  
A.G.H. Kessels ◽  
T. van der Weijden ◽  
A.V.R.J. Bell ◽  
...  

2008 ◽  
Vol 11 (6) ◽  
pp. A472 ◽  
Author(s):  
BA Essers ◽  
V Tjan Heijnen ◽  
JL Severens ◽  
A Novák ◽  
U Oron ◽  
...  

2020 ◽  
Vol 21 ◽  
Author(s):  
Sonali Mehendale-Munj

: Breast Cancer Resistance Protein (BCRP) is an efflux transporter responsible for causing multidrug re-sistance(MDR). It is known to expel many potent antineoplastic drugs, owing to its efflux function. Efflux of chemothera-peutics because of BCRP develops resistance to manydrugs, leading to failure in cancer treatment. BCRP plays an important role in physiology by protecting the organism from xenobiotics and other toxins. It is a half-transporter affiliated to theATP-binding cassette (ABC) superfamily of transporters, encoded by the gene ABCG2 and functions in response to adenosine triphosphate (ATP). Regulation of BCRP expression is critically controlled at molecular levels which help in maintaining the balance of xenobiotics and nutrients inside the body. Expression of BCRP can be found in brain, liver, lung cancers and acute myeloid leukemia (AML). Moreover, it is also expressed at high levels in stem cells and many cell lines. This frequent expression of BCRP has an impact on the treatment procedures and if not scrutinized may lead to failure of many cancer therapies.


Author(s):  
Lauren Marshall ◽  
Isabel Löwstedt ◽  
Paul Gatenholm ◽  
Joel Berry

The objective of this study was to create 3D engineered tissue models to accelerate identification of safe and efficacious breast cancer drug therapies. It is expected that this platform will dramatically reduce the time and costs associated with development and regulatory approval of anti-cancer therapies, currently a multi-billion dollar endeavor [1]. Existing two-dimensional (2D) in vitro and in vivo animal studies required for identification of effective cancer therapies account for much of the high costs of anti-cancer medications and health insurance premiums borne by patients, many of whom cannot afford it. An emerging paradigm in pharmaceutical drug development is the use of three-dimensional (3D) cell/biomaterial models that will accurately screen novel therapeutic compounds, repurpose existing compounds and terminate ineffective ones. In particular, identification of effective chemotherapies for breast cancer are anticipated to occur more quickly in 3D in vitro models than 2D in vitro environments and in vivo animal models, neither of which accurately mimic natural human tumor environments [2]. Moreover, these 3D models can be multi-cellular and designed with extracellular matrix (ECM) function and mechanical properties similar to that of natural in vivo cancer environments [3].


2010 ◽  
Vol 127 (3) ◽  
pp. 721-727 ◽  
Author(s):  
E. Bastiaannet ◽  
A. J. M. de Craen ◽  
P. J. K. Kuppen ◽  
M. J. Aarts ◽  
L. G. M. van der Geest ◽  
...  

PLoS ONE ◽  
2018 ◽  
Vol 13 (2) ◽  
pp. e0193338 ◽  
Author(s):  
Robbin H. Ophuis ◽  
Joran Lokkerbol ◽  
Mickaël Hiligsmann ◽  
Silvia M. A. A. Evers

2020 ◽  
Vol 152 ◽  
pp. S77-S78
Author(s):  
M. Verhoeven ◽  
M. Sangen van der ◽  
C. Hurkmans ◽  
L. Boersma ◽  
K. Verhoeven ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document